MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

NCT02364713 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

17

Enrollment

OTHER

Sponsor class

Stopped poor accrual

Conditions

Fallopian Tube Carcinosarcoma
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma
Fallopian Tube Serous Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Fallopian Tube Undifferentiated Carcinoma
Ovarian Carcinosarcoma
Ovarian Clear Cell Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Mucinous Adenocarcinoma
Ovarian Seromucinous Carcinoma
Ovarian Serous Adenocarcinoma
Ovarian Transitional Cell Carcinoma
Ovarian Undifferentiated Carcinoma
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Primary Peritoneal Carcinosarcoma
Primary Peritoneal Clear Cell Adenocarcinoma
Primary Peritoneal Endometrioid Adenocarcinoma
Primary Peritoneal Serous Adenocarcinoma
Primary Peritoneal Transitional Cell Carcinoma
Primary Peritoneal Undifferentiated Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions

BIOLOGICAL: Bevacizumab
DRUG: Gemcitabine Hydrochloride
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
DRUG: Paclitaxel
DRUG: Pegylated Liposomal Doxorubicin Hydrochloride
OTHER: Quality-of-Life Assessment
DRUG: Topotecan Hydrochloride

Sponsor

Mayo Clinic